Australia's most trusted
source of pharma news
Posted 25 November 2021 AM
In what is already shaping up to be a bumper 2022, PBAC has dropped a hefty agenda for its first meeting of the year with 35 new listings up for consideration in March.
Many of the medicines on the table are yet to be TGA approved, indicating these companies have submitted their new drugs via parallel processing and hint at new arrivals, potentially this year or by early 2022.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.